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Abstract
Background: Pancreatic cancer is a rare tumor with an extremely low survival rate. Its known risk factors include
the chronic use of tobacco and excessive alcohol consumption and the presence of chronic inflammatory diseases,
such as pancreatitis and type 2 diabetes. Angiogenesis and lymphangiogenesis, which have been the focus of
recent research, are considered prognostic factors for cancer development. Knowing the angiogenic and
lymphangiogenic profiles of a tumor may provide new insights for designing treatments according to the different
properties of the tumor. The aim of this study was to evaluate the density of blood and lymphatic vessels, and the
expression of VEGF-A, in pancreatic adenocarcinomas, as well as the relationship between blood and lymphatic
vascular density and the prognostically important clinical-pathological features of pancreatic tumors.
Methods: Paraffin blocks containing tumor samples from 100 patients who were diagnosed with pancreatic cancer
between 1990 and 2010 were used to construct a tissue microarray. VEGF expression was assessed in these samples
by immunohistochemistry. To assess the lymphatic and vascular properties of the tumors, 63 cases that contained
sufficient material were sectioned routinely. The sections were then stained with the D2-40 antibody to identify the
lymphatic vessels and with a CD34 antibody to identify the blood vessels. The vessels were counted individually
with the Leica Application Suite v4 program. All statistical analyses were performed using SPSS 18.0 (Chicago, IL, USA)
software, and p values ≤ 0.05 were considered significant.
Results: In the Cox regression analysis, advanced age (p=0.03) and a history of type 2 diabetes (p=0.014) or chronic
pancreatitis (p=0.02) were shown to be prognostic factors for pancreatic cancer. Blood vessel density (BVD) had no
relationship with clinical-pathological features or death. Lymphatic vessel density (LVD) was inversely correlated with
death (p=0.002), and by Kaplan-Meyer survival analysis, we found a significant association between low LVD (p=0.021),
VEGF expression (p=0.023) and low patient survival.
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Conclusions: Pancreatic carcinogenesis is related to a history of chronic inflammatory processes, such as type 2
diabetes and chronic pancreatitis. In pancreatic cancer development, lymphangiogenesis can be considered an early
event that enables the dissemination of metastases. VEGF expression and low LVD can be considered as poor
prognostic factors as tumors with this profile are fast growing and highly aggressive.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5113892881028514
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Prognosis
Background
Pancreatic cancer is a rare tumor, according to the World
Health Organization (WHO). The survival rate of patients
is extremely low, and as such, it is considered as one of
the most aggressive tumor types [1].
There are two types of cells in the pancreas, the exocrine
cells and endocrine cells. The most common pancreatic
tumors are originated from exocrine (epithelial) cells and
trerefore are classified as adenocarcinomas. The adenocar-
cinomas account for up to 90% of pancreatic cancer cases.
Pancreatic adenocarcinoma is considered rare before the
age of 30 years and becomes more common after the age
of 60 years.
The use of tobacco and its derivatives is considered
the main risk factor for pancreatic cancer development as
it increases the chance of pancreatic cancer development
by three times compared with non-smokers. Other risk
factors include the excessive consumption of alcoholic
beverages, meat and fat and the presence of some diseases,
such as chronic pancreatitis or type 2 diabetes (DM 2), as
well as a family history of cancer [1].
Angiogenesis is considered as one of the most import-
ant factors for tumor development and progression.
However, this process is also physiologically important
[2]. Lymphangiogenesis, characterized by the growth of
new lymphatic vessels, is absent in adults and is only
present during the embryonic stage [3]. Angiogenesis and
lymphangiogenesis can be found in pathological situations,
such as chronic inflammation, wound healing and several
neoplasms [3,4]. Both processes are induced by cytokines
and growth factors, with the Vascular Endothelial Growth
Factor family members (VEGFs) being the most important
factors. While it is known that VEGF-C and VEGF-D
are exclusively involved in lymphangiogenesis, studies
have demonstrated that VEGF-A, which is present at a
higher concentration and is associated with angiogenesis,
also has an important role in tumor lymphangiogenesis
[5,6]. The dynamic mechanisms of action of these growth
factors and their receptors are still being investigated [3].
The activation of oncogenes due to genomic instability,
as well as the action of some cytokines that increase the
expression of VEGFs, also act as specific survival factors
of endothelial cells, which support the development and
progression of tumor cells [2,7].
During the neoplastic process, angiogenesis supplies
nutrients to the primary tumor. At a later stage, the newly
formed vessels provide routes for tumor cells to migrate,
thus leading to metastasis in a process referred to as
hematogenous spread. However, the dissemination of
tumor cells via the lymphatic system is regarded as the
main factor for the development of metastases in the
regional lymph nodes and other distant organs [8,9].
In this way, both angiogenesis and lymphangiogenesis are
considered important in cancer development. Knowing the
angiogenic and lymphangiogenic profiles of a tumor may
provide new insights that may enable targeted treatments
according to tumor behavior [2,3,10,11].
The aim of this study was to evaluate the density of blood
and lymphatic vessels, and the expression of VEGF-A,
in pancreatic adenocarcinomas, as well as the relationship
between blood and lymphatic vessel density (BVD and
LVD) and the prognostically important clinical-pathological
factors in pancreatic tumors.
Methods
Clinical characteristics of patients
In June 2012 we requested the medical records containing
the clinical data of patients with pancreatic cancer diag-
nosed between 1990 and 2010 from the Medical Archive
Service of our Institution. The samples had been collected
from January 1990 to December 2010. The sampling
procedure applied for diagnostic purpose was in accordance
with current literature [12]. We excluded patients with
a previous history of cancer or any type of oncologic
treatment prior to the diagnosis of pancreatic cancer.
In the assessment of medical records, we obtained infor-
mation concerning clinical data, such as age, gender
and self-reported ethnicity. The following data were
also retrieved: involvement of lymph nodes, presence of
metastasis, disease-specific survival (DSS) and death. Fac-
tors that have been previously reported to contribute to
the development of pancreatic cancer, such as DM 2,
chronic pancreatitis and tobacco or alcohol consumption
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were also evaluated. Patients with insufficient clinical data
from the medical records were excluded from the study.
The slides of these patients were retrieved from the
Pathologic Service, and a pathologist (ARS) confirmed the
diagnosis of pancreatic cancer, as well as the histological
grade of the tumors.
One hundred patients who had sufficient clinical data
and a sufficient amount of tumor sample in the paraffin
blocks were included in the study.
The study was carried out in accordance with the 1975
Declaration of Helsinki and was approved by the local
research ethics committee (Comitê de Ética em Pesquisa
do Hospital das Clínicas da Faculdade de Medicina de
Ribeirão Preto).
Tissue Microarrays (TMA)
For the selection of tissues to be included in the TMA
block, archived slides that were previously stained
with hematoxylin and eosin were examined. All TMA
processing was carried out in the Department of Pathologic
Anatomy of A. C. Camargo Cancer Center (São Paulo,
Brazil). Next, 1.1 mm2 cylindrical areas that corresponded
to the most representative area of each lesion were
removed from the paraffin blocks and transferred to a
receiver block using a Manual Tissue Arrayer I (Beecher
Instruments, Silver Spring, USA).
Each cylinder on the TMA slide represented one patient.
From the TMA block, 3-μm histological sections were cut
using a conventional rotary microtome (Microm HM315,
Walldorf, Germany) and transferred to a TMA slide using
the paraffin tape-transfer system (Instrumedics, Saint Louis,
USA), according to manufacturer's instructions.
Immunohistochemistry (IHC)
All samples retrieved had been fixed in 4% neutral formalin
and embedded in paraffin. Of the 100 selected cases, only
63 contained sufficient material for traditional sectioning
and counting of the blood and lymphatic vessels. The IHC
reactions were developed using Reveal HRP (Spring –
Code SPD-125). The paraffin sections were de-waxed in
xylene and rehydrated through a series of graded alcohols.
The sections were placed in 10 mM citrate buffer (pH 6)
and were subjected to heat retrieval using a vapor lock for
30 minutes.
After antigen retrieval, the samples were allowed to
cool for 15 minutes at room temperature. Endogenous
peroxidase activity and proteins were blocked according to
the manufacturer's protocol. The specimens were incubated
at 4°C overnight with the following primary antibodies: D2-
40 (Lymphatic Marker) (1:300, D2-40 clone, Biocare Med-
ical, Concord, USA) for microvascular lymphatic counting,
Endothelial Cell Marker (CD34) (1:200, QBEnd/10 clone,
Novocastra Laboratories, Newcastle upon Tyne, UK) for
blood vessels counting and VEGF (1:100, A-20 clone,
Santa Cruz Biotechnology), which recognizes the isoforms
with splicing at the 121, 165 and 189 amino acids.
After the incubation with primary antibody, the slides
were incubated with the visualization system and then with
the chromogen substrate, liquid diaminobenzidine (DAB).
The slides were then stained with hematoxylin, dehydrated
in a series of alcohols and permanently mounted with
Permount polymer (Fischer, Fairlawn, NJ). Negative controls
were prepared by the omission of the primary antibody.
We used a 10% cut off for the quantitative analysis of
VEGF-positive neoplasic cells. As such, samples were
considered positive when 10% or more cells showed
cytoplasmatic VEGF expression, and samples were consid-
ered negatives if VEGF expression was absent or present
in less than 10% of cells [13,14].
Tumoral blood and lymphatic vessel counting
The blood and lymphatic vessel density was analyzed
according to Lin et al. [8] and Weidner et al. [15]. The
hotspots within the tumor sections were identified
under low magnification (50 and 100x) using a light
microscope. After the area of high microvascular dens-
ity within the tumor was defined, the microvessels
were counted individually under higher magnification
(200 and 400x) with the Leica Application Suite v4 program
(Leica Microsystems, Switzerland). Photomicrographs were
also obtained using the same program. The lymphatic
vessels were identified by immunohistochemical reaction
with the D2-40 antibody, which resulted in the brown
staining of the endothelial cells. The blood vessels were
identified by reaction with the CD34 antibody, which
resulted in the brown staining of the blood vessels. The
BVD and LVD counts were performed separately on
different slides.
Statistical analysis
The statistical analysis of the relationship between the
pathological and clinical data and the immunohistochemi-
cal results was performed by Fisher’s exact test and
Chi-square test. Univariate analysis was conducted by the
Kaplan-Meier method and Cox’s multiple regression
was used for multivariate analysis. For both the clinical
and pathological analyses and survival analysis, p<0. We
05 was considered statistically significant. All statistical
analysis was performed using SPSS 18.0 (Chicago, IL,
USA) software.
Results
Of the paraffin blocks obtained from the Pathology Service,
we excluded cases that did not have enough material
for immunohistochemical reactions and/or for BVD and
LVD counting or those for which the clinical information
necessary for the research was not available. As such, this
study was comprised of 100 cases for VEGF expression
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analysis by TMA and for epidemiologic study (clinical data)
and 63 cases for the BVD and LVD analysis.
Of these 100 cases, 52% were men and 48% were women.
With respect to self-reported ethnicity, 80% of the patients
declared themselves white, 15.3% mixed race and 4.6%
black. The ages at diagnosis ranged from 37 to 95 years
(mean, 62 years). The median survival of this research
population was 9.5 months, 67.6% of the patients had
metastases, and 84.6% had died by the end date of the
records search. Only 3.17% of patients had more than
4-year disease-specific survival.
Independent prognostic factors
In the Cox regression analysis, the BVD and LVD did not
have independent prognostic value for pancreatic cancer
(p=0.885 and p=0.103, respectively). Among the data
analyzed, only age (p=0.03), DM 2 (p=0.014) and chronic
pancreatitis history (p=0.02) were statistically significant
(Table 1).
Blood and lymphatic vessel density analysis
The average values of BVD and LVD were calculated
from two hotspots from the same slide. The highest
BVD and LVD values observed were more than 100
microvessels per field, while the lowest value found was
7 blood microvessels per field; there was an absence of
neoformed lymphatic microvessels in this latter specimen.
The data were dichotomized for the statistical analysis by
identifying the average value for the blood and lymphatic
vessels counted, which was 58 vessels per field for blood
vessels and 15 vessels per field for lymphatic vessels. We
considered values under 58 as low BVD and values above
58 blood vessels per field as high BVD and values lower
than 15 as low LVD and values above 15 vessels per field
as high LVD (Figure 1).
When the LVD and clinical-pathological parameters
were compared, we found an inverse relationship between
LVD and death events (p=0.002), while BVD had no
significant relationship with death events (Table 2).
VEGF Expression
Of the 100 cases analyzed by TMA, 71 specimens showed
positive cytoplasmic VEGF staining, while 16 were nega-
tive, and 12 specimens were lost because of the technique
(Figure 2).
Correlation between BVD, LVD, and VEGF Expression
and disease-specidic survival
The disease-specific survival of the patients ranged from 1
to 69 months (mean, 9.5 months). Using the Kaplan-Meyer
survival analysis with log-rank test, we found a significant
association between low LVD and low patient survival
(p=0.021) (Figure 3) and between VEGF expression and
low patient survival (p=0.023) (Figure 3). However, we did
not find any association between BVD and patient survival
(p=0.175).
Discussion
In our work we include only adenocarcinomas because
they are far more comum than the pancreatic tumors
of endocrine origins. However, it is worthwhile say that
pancreatic tumors of endocrine origin are less aggressive
than carcinomas, with distinct prognostic parameters [16].
The epidemiology for pancreatic cancer (adenocarcinoma)
is heterogeneous, differing from one geographic region to
another and in comparison to other types of tumors better
studied, such as breast, prostate, lung and colorectal, little
is known about the cellular and molecular prognostic
factors of this disease. This knowledge gap is mainly due
to the high aggressiveness of pancreatic tumors, which
results in fewer than 5% of patients with 5-year survival
after diagnosis. Additionally, pancreatic cancer presents
with very subtle symptoms due to the retroperitoneal
location of the organ [17]. Our study showed that in the
studied population, only 3.17% of the patients achieved
a survival rate of more than 4 years and that the average
survival was 9.5 months, which is similar to the pancreatic
cancer world statistics [17-20].
According to previous studies, men are more likely to
develop pancreatic cancer, and the difference between the
genders is higher in developed countries than in developing
countries. The same trend was found in our study, in which
52% of the patients were men and 48% were women.
Although pancreatic cancer is not among the ten most
common cancers, its incidence tends to increase over
time. In developing countries, this is mainly due to two
primary reasons, increased life expectancy and the adoption
of risk behavior, including high calorie and fatty food intake
and consumption of tobacco and alcoholic beverages, at
early ages [17,20].
Klöppel et al. [20] reported that 80% of pancreatic cancer
cases are diagnosed in patients between 60 to 80 years of
age. In our study, the average age of diagnosis was 65 years
Table 1 Independent prognostic factors
Variable Exp(B) 95% CI for Exp(B) Sig.
Lower Upper
Age 0.074
Age (1) 0.483 0.082 2.837 0.42
Age (2) 0.131 0.021 0.825 0.03*
DM 2 0.228 0.07 0.743 0.014*
Chronic Pancreatitis 6.268 1.337 29.38 0.020*
VEGF-A 0.31 0.047 2.053 0.224
BVD 0.892 0.191 4.168 0.885
LVD 3.061 0.797 11.761 0.103
Multivariate analysis of clinical-pathological data, BVD, LVD and VEGF expression.
*A value of p<0.05 were considered significant.
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and ranged from 37 years to 95 years, which is consistent
with previous reports in the literature.
With respect to self-declared ethnicity, 80% of the
patients declared themselves white, 15.3% intermediate
and 4.6% black. This is in contrast to other studies that
have highlighted the black “race” as a risk factor for the
pancreatic cancer development [17,20]. However, Takikita
et al. [18] observed that in the cohort they studied, 75% of
the tumors were well- or moderately differentiated and
were significantly more common in whites than in other
races. This is despite a lack of detailed information in the
medical records of patients, as was the case in our study,
and which is barrier for epidemiological population studies.
Additionally, the high degree of mixing of the Brazilian
population between three main parental populations,
Native American, African and European, must be consid-
ered. As such, in scientific studies, the determination of
ethnicity based on self-declaration or through the amount
of pigment in the skin of the individual is debatable and is
a very subjective classification, especially in populations
with a high degree of miscegenation [21].
By multivariate analysis of the clinical-pathological data,
we identified some independent prognostic factors for
pancreatic cancer. An age higher than 74 years was an
independent factor (p=0.03) because the higher the age
of the individual, the greater the chance of developing
neoplasms. The risk with respect to old age is already well
known due to the duration allowing for the accumulation
of mutations in the cells, mainly in the pool of stem cells,
which multiply slowly. Over time, these cells acquire the
necessary mutations to maintain a balance between them
and the organ microenvironment [22]. Another significant
prognostic factor was a history of DM 2 (p=0.014) and
chronic pancreatitis (p=0.02), which demonstrated that they
may be risk factors for pancreatic cancer. These data are in
agreement with other several studies that have also identi-
fied DM 2 and chronic pancreatitis as risk factors [23-26].
Several studies have been conducted to clarify the rela-
tionship between DM 2, chronic pancreatitis and the risk
of developing pancreatic cancer. Prizment et al. [25]
showed that a particular single nucleotide polymorphism
(SNP) associated with diabetes may also be associated
with pancreatic cancer risk. Additionally, they observed
that there were more cases of DM 2 in patients diagnosed
with pancreatic cancer than among control patients who
did not have a diagnosis of cancer. Another hypothesis,
proposed by Braun, Bitton-Worms and LeRoith [23], was
that insulin resistance, chronic inflammation and oxidative
stress influence the development of pancreatic cancer be-
cause these processes are associated with both DM 2 and
chronic pancreatitis. When the pancreatic beta cells are
aberrantly hyperactive, the pancreatic tissue is exposed to
high levels of insulin, which in turn has growth-promoting
and mitogenic action, inducing cell proliferation. The
tumor cells have a mechanism for capturing glucose that
is independent from insulin, which confers a metabolic
advantage. It is known that the high concentration of
glucose in tissues leads to the formation of reactive
oxygen species (ROS) that activate pro-inflammatory
cytokines, which in turn, stimulate angiogenic factors
such as VEGF [24]. By immunohistochemistry with
CD34 and D2-40 antibodies, the blood and lymphatic
vessels were identified, counted and tabulated. For statis-
tical purposes, the values were dichotomized as low and
high BVD or LVD (Figure 1). By comparing the LVD and
the clinical-pathological parameters (Table 2), we found
an inverse relationship between LVD and death events
(p=0.002). No relationship was found between BVD and
the clinical-pathological parameters. A similar result was
found by Kaplan-Meyer survival curve analysis (Figure 3),
in which low LVD was also related to poor patient survival
and a bad prognosis (p=0.021).
The vascularization is considered an important step
for tumor progression [27], so it is surprising the lack of
association between BVD and prognostic parameters.
However, the absence of a relationship between BVD
and prognostic parameters found in our study was also
previously reported by Kawauchi et al. [28] in synovial
Figure 1 Microphotograph of pancreatic adenocarcinoma. A- Hotspot showing blood vessels stained by immunohistochemistry with CD34
antibody. B- Hotspot showing lymphatic vessels stained by immunohistochemistry with D2-40 antibody.
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sarcomas. In squamous cell carcinoma of the larynx,
Sullu et al. (2010) found that blood vessel density was
significantly higher in high-grade tumors but did not
correlate with other prognostic parmeters [29]. This lack
of correlation between BVD and prognostic parameters
could be due the tendency for pancreatic cancer to
metastasize via the lymphangiogenic pathway. However,
it also must be emphatizided that vascular diffusion
density may also be involved in this process since only
tumour cells within a distance less than 20 micro from
the nearest neighbouring vessel are considered important
for prognostic purpose [30].
The relationship between LVD and tumor behavior is
controversial and has only been recently reported in
the literature. Sleeman and Thiele [31] established a
relationship between LVD and lymph node metastases
in different types of tumors. Additionally, studies have
demonstrated a positive relationship between peritumoral
and/or intratumoral LVD, lymph node metastases and
poor prognosis in squamous cell head and neck, endomet-
rial and gastric tumors. On the other hand, no relationship
was observed in pancreatic, ovarian and transitional cell
bladder adenocarcinomas. Other reports have yielded
conflicting results, such as in breast, lung, colorectal and
oral esophageal cell tumors [32].
In pancreatic endocrine tumors, Rubbia-Brandt et al. [33]
found a relationship between LVD and tumor clinical
behavior. However, there was no relationship between
LVD and the presence of lymph node metastases. The
expression of VEGF-C, an inducer of lymphatic vessels,
was lower in benign tumors than in well-differentiated,
malignant tumors. These data show that high LVD is
not required for the proliferation of lymphatic vessels
and that the malignant transformation of the tumor leads
to the induction of pro-lymphangiogenic factors. Add-
itionally, despite the tendency for an increased number of
lymphatic vessels in the tumor over time, the invasion
of tumor cells into the lymph capillaries occurs early in
the tumorigenic process [33]. Similarly, Sipos et al. [34]
reported that the LVD in malignant tumors was increased
compared to that found in normal pancreas or in chronic
inflammation. However, the intratumoral LVD was low,
and the lymph vessels showed decreased proliferation,
rather than being stimulated due to the presence of
inflammatory factors. As such, functional intratumoral
lymphatic vessels are not required during lymphatic inva-
sion, and their loss of function can be caused by several
different mechanisms [35].
Because we observed an inverse relationship between
LVD and survival, we hypothesized that low LVD is due
to the accelerated growth of the tumor and the eventual
loss of function of the lymphatic vessels that were
present. Accordingly, tumors with low LVD are more
likely to be fast growing and of a more advanced stage,
which would explain the low survival rate of these
patients. The function of these vessels could have been
lost because of the internal pressure caused by rapid
tumor growth, which would lead to the collapse of the
vessels, the invasion of tumor cells in the lymph vessels
or other mechanisms that have yet to be elucidated
[35]. Some studies have suggested that despite the low
intratumoral LVD, one can still find a high peritumoral
LVD. These may be the vessels through which lymphatic
metastasis occurs, resulting in the spread of tumor cells to
Table 2 Relationship between the clinical-pathological
data and the lymphatic vascular density
Characteristics LVD p-value
< 15 vessels > 15 vessels
Gender 0.793
Male 22 12
Female 20 9
Age 0.884
<60 20 11
60-74 14 7
>74 8 3
Alcohol consumption 0.791
No 25 12
Yes 16 9
Tobacco consumption 1
No 26 13
Yes 15 8
DM 2 0.260
No 29 18
Yes 13 3
Chronic Pancreatitis 0.767
No 34 16
Yes 7 5
Histologic Grade 0.974
Well differentiated 12 6
Moderately differentiated 22 11
Poorly differentiated 5 3
Lymph node metastasis 0.165
No 26 10
Yes 12 11
Distant metastasis 0.287
No 14 10
Yes 28 11
Death 0.002*
No 2 8
Yes 40 13
*A value of p<0.05 were considered significant.
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the regional lymph nodes and, in the case of pancreatic
tumors, the liver [33,36].
In agreement with the research by Yin et al. [37], which
demonstrated the importance of the lymphangiogenesis in
the evolution of diabetes and pancreatic inflammation, our
work found these diseases to be independent prognostic
factors for pancreatic cancer. Furthermore, the formation
of new lymph vessels is an early process that develops
before tumorigenesis, and as the tumor grows, the lymph
vessels are inhibited or disabled. Our study also reports
the same prognostic importance of LVD that was found
by Wang et al. [38].
Of the 100 pancreatic tumor cases that were used to con-
struct the TMA and subsequently analyzed by immunohis-
tochemistry for VEGF expression, 71% showed cytoplasmic
VEGF expression. By Kaplan-Meyer survival curve analysis,
the expression of VEGF in tumors proved to be signifi-
cantly associated (p=0.023) with poor prognosis and a
reduction in patient survival time.
It is known that the VEGF family of proteins contributes
to the development of new blood vessels through the
process of angiogenesis, which was widely studied and
discussed by Folkman and reviewed by other researchers.
Angiogenesis leads to the spread of tumor cells by hema-
togenous routes and, consequently, to metastasis [39-42].
The involvement of other organs by metastases signifi-
cantly decreases the patient's survival. Additionally, the
overexpression of VEGFs by the tumor or cells in the
extracellular matrix leads to the rapid growth of the tumor
mass because these factors have mitogenic properties that
stimulate DNA synthesis in endothelial cells and provide
better nutrition and tumor oxygenation through the for-
mation of new blood vessels [43].
The family of VEGFs is composed of VEGF-A, VEGF-B,
VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth
factor (PlGF). VEGF-A was the first to be discovered and,
therefore, was originally named VEGF. This factor was
directly linked to angiogenesis that occurs in physiological
processes, such as embryonic development, and in patho-
logical processes, which include inflammation, wound
healing and tumor growth. The function of VEGF-B,
which is expressed in skeletal and cardiac muscle and
Figure 3 Survival curves according to lymphatic Vessel Density (LVD) and VEGF-A expression. A. Kaplan-Meyer plots analyzed by Mantel-
Cox’s log-rank model. Time between diagnosis and death or the last data recorded is represented as a function of dichotomized lymphatic
vascular density (p=0.021). DSS= disease-specific survival. B. Kaplan-Meyer plots analyzed by Mantel-Cox’s log-rank model. Time between
diagnosis and death or the last data recorded is represented as a function of VEGF expression (p=0.023). DSS= disease-specific survival.
Figure 2 Microphotograph of VEGF immunohistochemistry in pancreatic adenocarcinoma. A- VEGF-negative specimen.
B- VEGF-positive specimen.
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brown adipose tissue, is not understood. However, un-
like VEGF-A, its expression is not stimulated by low
temperatures or by hypoxia. VEGF-C and-D are linked
to lymphangiogenesis and, unlike VEGF-A, are only
expressed in lymphatic endothelial cells in physiological
situations. The most recently discovered factors are
VEGF-E, which is encoded by a virus, and VEGF-F, which
is expressed in the venom of a snake [43].
In our research, we used a VEGF antibody that,
according to the manufacturer, has affinity for the protein
isoforms with splicing in amino acids 121, 165 and 189,
which correspond to VEGF-A [44,45]. The relationship
that was observed between the presence of VEGF-A
and low survival can be accounted for by the mitogenic
activities of VEGF-A, which contribute to the rapid
growth of the tumor and, consequently, poor prognosis.
The independent prognostic factors identified in our
study, advanced age and a history of DM 2 or chronic
pancreatitis, are supported by the relationship between
inflammation and the increased expression of VEGF.
During inflammatory diseases, the chronic high concen-
trations of insulin, ROS, cytokines and inflammatory
mediators, such as TNF-α and COX-2, lead to an increase
the expression of pro-angiogenic factors, the most import-
ant being VEGF-A [23,24].
Even though VEGF-A is directly linked to angiogenesis,
recent studies have shown that this factor is also involved
in lymphangiogenesis during tumor development. The
biological effects of the VEGF family members occur
through the interaction of the factors, which are secreted
by tumor cells or matrix inflammatory cells, with trans-
membrane receptors located in the vascular and lymphatic
endothelial cells. The interaction of the ligand with receptor
leads to dimerization and the autophosphorylation of the
receptor intracellular domains that, in turn, generates a
cascade of reactions involving proteins related to cellular
survival and division. VEGF-A can interact with the re-
ceptors VEGFR-1, VEGFR-2 and the neuropilins 1 and
2. However, it is through interaction with the VEGFR-2,
found specifically in lymphatic endothelial cells, that
lymphangiogenesis is induced [43].
VEGF-A can promote lymphangiogenesis either indir-
ectly or directly. Indirectly, it can recruit inflammatory
cells that, in turn, will produce VEGF-C and VEGF-D,
which are known to promote lymphangiogenesis. Directly,
VEGF-A will interact with its receptor, VEGFR-2, which is
present in pre-existing lymphatic vessels, activating them
[5]. According to Wirzenius et al. [46], while the binding
of VEGF-A to VEGFR-3 affects the spreading of the vessel
network, its binding to VEGFR-2 produces an increase in
lymphatic vessels size, making them able to drain the
interstitial fluid of the tumors. In this way, VEGF-A
promotes the development of an ideal pre-metastatic
niche for the initiation of metastases [6].
VEGF expression is increased both at the transcription
and translation levels in pancreatic tumor tissues, com-
pared to surrounding non-tumoral tissue. Its expression,
according to Liang et al. [47], is related to tumor size,
stage and lymph node metastases, demonstrating it as
an important prognostic marker of tumor behavior.
In our study, we demonstrated that the LVD is inversely
related to survival, while the expression of VEGF-A is
directly related to survival. In accordance with the current
literature, we postulate that the expression of VEGF-A is
an early event in the development of cancer. Inflammatory
processes, which are known to increase the likelihood of
cancer development, also promote the overexpression of
VEGF-A [24,25,48]. The higher the expression of VEGF in
the tumor during its development, the faster the growth
of the tumor. In turn, this causes the previously developed
lymph vessels to be inactivated by the increased internal
pressure of the tumor and, consequently, they will collapse
and be destroyed [35].
Conclusions
We conclude that advanced age and a history of type 2
diabetes mellitus or chronic pancreatitis are independent
prognostic factors for the development of pancreatic
cancer. We also conclude that the expression of VEGF-
A and low LVD may contribute significantly to poor
prognosis because of increased tumor aggressiveness
and low patient survival. We add new evidences in litera-
ture that lymphatic vessel density is related to survival in
patients with pancreatic carcinoma and is relationship
with VEGF-A expression may be important for future
therapeutic strategies.
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